Form 4: Guardant Health CLO Executes Stock Sale
Insider Transaction Report
John G. Saia, Chief Legal Officer of Guardant Health, Inc., sold 10,000 shares of common stock on May 27, 2026.
Summary
- John G. Saia, Chief Legal Officer of Guardant Health, Inc., disposed of 10,000 shares of common stock.
- The transactions were executed on May 27, 2026, pursuant to a pre-arranged Rule 10b5-1 trading plan.
- 9,994 shares were sold at a weighted average price of $125.083 per share.
- 6 shares were sold at a price of $126.08 per share.
- Following these transactions, the reporting person retains beneficial ownership of 35,950 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-planned 10b5-1 arrangement, which is standard practice for executive financial planning.
Positives
- The sale was conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.
Negatives
- The transaction represents a reduction in the direct equity stake held by a key member of the executive leadership team.
Risks
- Executive stock sales can sometimes be perceived negatively by the market as a signal of management's view on the company's valuation or future prospects.
Future Outlook
No forward-looking guidance or operational outlook was provided in this filing.
Industry Context
StockSavvy.ai notes that executive divestments via 10b5-1 plans are common in the biotechnology sector and are typically viewed as routine liquidity events rather than indicators of operational distress.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage equity holdings while maintaining compliance with SEC regulations.
Stakeholder Impact
- Minimal impact expected as the sale was conducted via a pre-planned trading program.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 05/27/2026 | Date of the reported stock sale transactions. |
| 05/28/2026 | Date the Form 4 was signed and filed. |
Keywords
Guardant Health, GH, Insider Trading, Form 4, Executive Compensation, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.